Merck & Co., Inc. (NYSE:MRK) Releases FY 2026 Earnings Guidance

Merck & Co., Inc. (NYSE:MRK) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 2.660-2.760 for the period, compared to the consensus earnings per share estimate of 3.420. The company issued revenue guidance of $66.3 billion-$67.3 billion, compared to the consensus revenue estimate of $66.7 billion.

Merck & Co., Inc. Stock Performance

Shares of NYSE MRK traded up $2.71 during midday trading on Wednesday, hitting $130.71. 2,053,583 shares of the company’s stock were exchanged, compared to its average volume of 10,761,480. Merck & Co., Inc. has a twelve month low of $77.58 and a twelve month high of $135.05. The firm has a market cap of $322.83 billion, a P/E ratio of 36.82, a PEG ratio of 5.07 and a beta of 0.19. The stock’s 50 day moving average price is $123.45 and its 200-day moving average price is $118.78. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The firm had revenue of $16.61 billion for the quarter, compared to analysts’ expectations of $16.37 billion. During the same quarter in the previous year, the company earned $2.13 earnings per share. The firm’s quarterly revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Equities research analysts anticipate that Merck & Co., Inc. will post 2.74 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be given a $0.85 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 annualized dividend and a yield of 2.6%. Merck & Co., Inc.’s payout ratio is 95.77%.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on MRK. Wall Street Zen cut Merck & Co., Inc. from a “buy” rating to a “hold” rating in a report on Monday, July 20th. Citigroup initiated coverage on shares of Merck & Co., Inc. in a research note on Wednesday, May 6th. They set a “neutral” rating and a $125.00 price objective for the company. CICC Research assumed coverage on shares of Merck & Co., Inc. in a research report on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 target price on the stock. Weiss Ratings lowered Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday, May 15th. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $142.00 price objective on shares of Merck & Co., Inc. in a research report on Wednesday, July 8th. Thirteen research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $134.56.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Q2 results exceeded expectations: Merck reported revenue of $16.61 billion, above the $16.37 billion consensus, while its adjusted loss of $0.13 per share was narrower than the expected $0.26 loss. Revenue rose 5.1% year over year, led by oncology products and newer launches. Merck posts better-than-expected second-quarter results on Keytruda strength
• Positive Sentiment: Keytruda franchise remains strong: Sales of the injectable version of Keytruda reportedly surpassed Wall Street expectations by more than $200 million, reinforcing demand for Merck’s leading cancer portfolio and its strategy for managing the eventual post-Keytruda transition. The Merck Product That Absolutely Demolished Wall Street’s Forecasts
• Positive Sentiment: 2026 sales outlook raised: Merck increased its full-year revenue guidance to $66.3 billion-$67.3 billion, supported by pipeline progress and growth from recently launched products. Guggenheim also raised its price target to $146 and maintained a Buy rating, implying further upside from current trading levels. MRK Q2 Earnings Call Puts Pipeline Progress in Focus
• Neutral Sentiment: Pipeline progress is mixed: Merck is evaluating tulisokibart in multiple indications, but discontinued its study in systemic sclerosis-associated interstitial lung disease. The setback is limited to one indication but highlights development risk as investors assess Merck’s post-KEYTRUDA growth prospects. MSD posts a victory and defeat for anti-TL1A
• Negative Sentiment: Profit outlook was reduced: Merck set 2026 EPS guidance at $2.66-$2.76, well below the $3.42 analyst consensus, primarily because of charges related to its Terns Pharmaceuticals acquisition. The company’s reported quarterly loss also compares unfavorably with year-ago earnings of $2.13 per share. Merck hikes revenue outlook but cuts profit guidance

Hedge Funds Weigh In On Merck & Co., Inc.

Institutional investors have recently made changes to their positions in the business. Sunbeam Capital Management LLC raised its stake in shares of Merck & Co., Inc. by 1.3% in the fourth quarter. Sunbeam Capital Management LLC now owns 7,099 shares of the company’s stock valued at $747,000 after purchasing an additional 94 shares in the last quarter. Rexford Capital Inc. increased its holdings in shares of Merck & Co., Inc. by 1.3% during the fourth quarter. Rexford Capital Inc. now owns 7,799 shares of the company’s stock worth $821,000 after buying an additional 100 shares in the last quarter. Wealthspire Retirement LLC boosted its stake in Merck & Co., Inc. by 2.3% in the fourth quarter. Wealthspire Retirement LLC now owns 5,162 shares of the company’s stock worth $543,000 after purchasing an additional 114 shares in the last quarter. Financial Engines Advisors L.L.C. raised its stake in shares of Merck & Co., Inc. by 1.3% in the third quarter. Financial Engines Advisors L.L.C. now owns 9,783 shares of the company’s stock worth $821,000 after acquiring an additional 125 shares during the last quarter. Finally, Monetary Management Group Inc. lifted its holdings in Merck & Co., Inc. by 0.7% during the 2nd quarter. Monetary Management Group Inc. now owns 19,035 shares of the company’s stock worth $1,507,000 after buying an additional 125 shares in the last quarter. 76.07% of the stock is currently owned by institutional investors.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.